Herbs (Global Traditional) · Ayurveda
Boswellia (Boswellia serrata) (Boswellia serrata)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Boswellia serrata contains boswellic acids that inhibit 5-lipoxygenase enzyme, reducing inflammatory leukotriene production. This Ayurvedic resin traditionally supports joint health and inflammatory conditions through multiple anti-inflammatory pathways.
Boswellia serrata is a tree native to India's dry regions, particularly the western Ghats and Deccan peninsula, belonging to the Burseraceae family. Its oleo-gum-resin (frankincense) is harvested by making bark incisions to collect the hardened resinous tears, which are extracted using methods like hydro-distillation, steam distillation, or supercritical CO₂ extraction.
The research dossier reveals no human clinical trials, RCTs, or meta-analyses for Boswellia serrata were found in the search results. No PubMed PMIDs for clinical studies are available, with evidence limited to traditional use documentation and in-vitro antioxidant activity studies.
No clinically studied dosage ranges for extracts, powder, or standardized forms are available in the current research. Analytical standardization targets boswellic acids content (10-21% in typical extracts), but therapeutic doses have not been established through clinical trials. Consult a healthcare provider before starting any new supplement.
Boswellia serrata resin is not a significant source of macronutrients or conventional micronutrients and is used in concentrated extract or resin form rather than as a food. Primary bioactive compounds are pentacyclic triterpenic acids, most notably boswellic acids, which constitute approximately 25–35% of the dry resin weight. Key boswellic acids include: 11-keto-β-boswellic acid (KBA, ~5–8% of resin), acetyl-11-keto-β-boswellic acid (AKBA, ~3–6% of resin, considered the most pharmacologically active), α-boswellic acid, β-boswellic acid, acetyl-α-boswellic acid, and acetyl-β-boswellic acid. Standardized commercial extracts (e.g., 'Shallaki' or branded forms like '5-Loxin' or 'AprèsFlex') are typically standardized to 30–65% total boswellic acids and ≥10–20% AKBA. The essential oil fraction (approximately 3–8% of resin by steam distillation; higher yields ~10–14% via supercritical CO₂) contains predominantly monoterpenes and sesquiterpenes including α-thujene, α-pinene (~40–60% in some chemotypes), limonene, sabinene, and incensole acetate. Polysaccharides (arabinogalactans) are present in the water-soluble gum portion (~35–65% of crude gum-resin). Bioavailability of boswellic acids, particularly AKBA, is notably poor via oral administration due to high lipophilicity and first-pass metabolism; absorption is significantly enhanced (up to 4.77-fold for AKBA) when taken with a high-fat meal or formulated with phospholipid complexes or piperine. Typical effective studied doses range from 100–400 mg of standardized extract (≥30% boswellic acids) daily. Conventional nutritional constituents (calories, carbohydrates, vitamins, dietary minerals) are not meaningfully present at supplemental doses and have not been characterized for dietary contribution.
Boswellic acids, particularly 11-keto-β-boswellic acid (KBA) and acetyl-11-keto-β-boswellic acid (AKBA), selectively inhibit 5-lipoxygenase enzyme, reducing pro-inflammatory leukotriene synthesis. These compounds also modulate NF-κB signaling pathway and inhibit elastase enzyme activity. The supercritical CO₂ extracted essential oils demonstrate potent free radical scavenging activity up to 96% through antioxidant mechanisms.
Current evidence consists primarily of in-vitro studies demonstrating anti-inflammatory and antioxidant activities of boswellic acids. Traditional use documentation supports applications for chronic inflammatory conditions, but high-quality human clinical trials with standardized extracts are limited. Most available research focuses on isolated compound studies rather than whole extract efficacy. Evidence quality remains at traditional use and laboratory study levels, requiring more robust clinical validation.
Boswellia serrata is generally well-tolerated with mild gastrointestinal side effects reported in some users. No major drug interactions are documented, but theoretical interactions may exist with anti-inflammatory medications due to additive effects. Safety during pregnancy and lactation has not been established through clinical studies. Individuals with autoimmune conditions should consult healthcare providers before use due to immune system modulation effects.
